Authors: Ľ. Minařík Authors‘ workplace: I. interní klinika – klinika hematologie, VFN v Praze BIOCEV, 1. LF UK, Vestec Published in: Transfuze Hematol. dnes,32, 2026, No. 1, p. 22-27. Category: Review/Educational Papers doi: https://doi.org/10.48095/cctahd202605
In 2025, the combination of azacitidine (AZA) and venetoclax (VEN) is the standard treatment for older patients with acute myeloid leukaemia (AML) who are not candidates for intensive induction chemotherapy. VEN+AZA has been shown to increase complete remission rates and prolong overall survival. The current treatment regimen is based on the results of the VIALE-A study.
acute myeloid leukaemia (AML) – non-intesive therapy – venetoclax (VEN) – azacitidine (AZA)
1. Pollyea DA, Stevens BM, Jones CL, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018; 24 (12): 1859–1866.
2. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383 : 617–629.
3. Pratz KW, Jonas BA, Pullarkat V, et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024; 99 (4): 615–624.
4. DiNardo CD, Pratz KW, Panayiotidis P, et al. The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2025; 100 (1): 185–188.
5. Marvin-Peek J, Garcia JS, Borthakur G, et al. A Phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated hematologic malignancies: a 2024 update. Blood. 2024; 144 (Suppl 1): 219.
6. Venditti A, Hou J-Z, Fenaux P, et al. Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model. Leukemia. 2025; 39 : 2697–2707.
7. Othman J, Lam HPJ, Leong S, et al. Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS. Blood Neoplasia. 2024; 1 (3): 100017.
8. Acker F, Chromik J, Tiedjen E, et al. Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy. Eur J Haematol. 2024; 113 (5): 623–630.
9. Chen Y, Wang Z, Cai R, et al. Significant prognostic improvement in elderly patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax: outcomes from a retrospective real-world analysis. Ann Med. 2025; 57 (1): 2512120.
10. Dluhosova B, Visek B, Valka J, et al. Real-world experience with venetoclax-based therapy in acute myeloid leukemia: insights from the Czech Republic. Clin Lymphoma Myeloma Leuk. 2025; 25 (12): e1022–e1032.
11. Tiong IS, Wall M, Bajel A, et al. How comparable are patient outcomes in the „real-world“ with populations studied in pivotal AML trials? Blood Cancer J. 2024; 14 (1): 54.
Prohlášení o konfliktu zájmů
Příprava rukopisu byla podpořena firmou Abbvie.
Do redakce doručeno dne: 18. 11. 2025.
Přijato po recenzi dne: 26. 1. 2026.
MUDr. Ľubomír Minařík, PhD.
I. interní klinika – klinika hematologie
VFN v Praze
U nemocnice 499/2
128 08 Praha 2
BIOCEV
1. LF UK
Průmyslová 595
252 50 Vestec
e-mail: lubomir.minarik@vfn.cz
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
